Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PD-1 Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05311566
What this trial is testing

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Who this might be right for
Cervical CarcinomaChemoradiotherapyAnti-programmed Cell Death Receptor 1+6 more
Lei Li 92
Large-scale testing (Phase 3)UnknownNCT03950154
What this trial is testing

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital 198
Early research (Phase 1)Active Not RecruitingNCT07407985
What this trial is testing

A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors

Who this might be right for
Solid Tumors
Tianjin Medical University Cancer Institute and Hospital 15
Testing effectiveness (Phase 2)Study completedNCT02636010
What this trial is testing

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 20
Testing effectiveness (Phase 2)UnknownNCT05246982
What this trial is testing

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
Shanghai Henlius Biotech 40
Post-approval studies (Phase 4)UnknownNCT04331626
What this trial is testing

Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Henan Cancer Hospital 50
Not applicableLooking for participantsNCT05392413
What this trial is testing

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

Who this might be right for
Esophageal Squamous Cell CarcinomaPD-1 Inhibitor
Nanfang Hospital, Southern Medical University 200
Testing effectiveness (Phase 2)UnknownNCT04667793
What this trial is testing

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

Who this might be right for
Thymic Epithelial Tumor
Shanghai Pulmonary Hospital, Shanghai, China 15
Testing effectiveness (Phase 2)Looking for participantsNCT05187338
What this trial is testing

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Who this might be right for
Lung CancerLiver CancerColorectal Cancer+8 more
Second Affiliated Hospital of Guangzhou Medical University 100
Testing effectiveness (Phase 2)UnknownNCT05193214
What this trial is testing

A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Who this might be right for
Sarcoma, Soft Tissue
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT07690787
What this trial is testing

JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma

Who this might be right for
Recurrent/ Metastatic NPC
Chinese University of Hong Kong 49
Testing effectiveness (Phase 2)Looking for participantsNCT06532617
What this trial is testing

Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04725474
What this trial is testing

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

Who this might be right for
Solid Tumor, Adult
CatalYm GmbH 199
Testing effectiveness (Phase 2)UnknownNCT03817658
What this trial is testing

A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC

Who this might be right for
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 725
Early research (Phase 1)Active Not RecruitingNCT07340476
What this trial is testing

Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects

Who this might be right for
Healthy Male Subjects
Akeso 108
Testing effectiveness (Phase 2)Study completedNCT02628132
What this trial is testing

Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients

Who this might be right for
Breast Cancer
King Faisal Specialist Hospital & Research Center 22
Testing effectiveness (Phase 2)Looking for participantsNCT05430698
What this trial is testing

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Who this might be right for
Perihilar Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 62
Not applicableUnknownNCT04360655
What this trial is testing

Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC

Who this might be right for
Effect IncreasedSafety Issues
Shanghai Pulmonary Hospital, Shanghai, China 50
Early research (Phase 1)Study completedNCT04649385
What this trial is testing

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
BeiGene 157
Early research (Phase 1)Study completedNCT05216835
What this trial is testing

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Classical Hodgkin Lymphoma
AstraZeneca 45
Next Page